

Weijing Sun, Facp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/741529/publications.pdf>

Version: 2024-02-01

65
papers

2,113
citations

304743

22
h-index

254184

43
g-index

68
all docs

68
docs citations

68
times ranked

3658
citing authors

#	ARTICLE	IF	CITATIONS
1	Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma. <i>JAMA Oncology</i> , 2019, 5, 1431.	7.1	417
2	The Role of Angiogenesis in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 912-920.	7.0	345
3	Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. <i>Journal of Hepatology</i> , 2018, 69, 353-358.	3.7	270
4	A phase 2 trial of regorafenib as a single agent in patients with chemotherapyâ€refractory, advanced, and metastatic biliary tract adenocarcinoma. <i>Cancer</i> , 2019, 125, 902-909.	4.1	98
5	Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy. <i>Journal of Hematology and Oncology</i> , 2012, 5, 63.	17.0	97
6	Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma. <i>Cancer</i> , 2018, 124, 3520-3527.	4.1	66
7	Estimation of Symptom Severity During Chemotherapy From Passively Sensed Data: Exploratory Study. <i>Journal of Medical Internet Research</i> , 2017, 19, e420.	4.3	57
8	The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials. <i>Journal of Hematology and Oncology</i> , 2021, 14, 13.	17.0	49
9	Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review. <i>BMC Cancer</i> , 2020, 20, 507.	2.6	48
10	Gastric cancer: current and evolving treatment landscape. <i>Chinese Journal of Cancer</i> , 2016, 35, 83.	4.9	47
11	Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. <i>Journal of Hematology and Oncology</i> , 2015, 8, 44.	17.0	40
12	Metastatic Tumor-in-a-Dish, a Novel Multicellular Organoid to Study Lung Colonization and Predict Therapeutic Response. <i>Cancer Research</i> , 2019, 79, 1681-1695.	0.9	40
13	Cancer immunotherapy in clinical practice: the past, present, and future. <i>Chinese Journal of Cancer</i> , 2014, 33, 445-457.	4.9	38
14	A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone. <i>Investigational New Drugs</i> , 2017, 35, 189-197.	2.6	33
15	Tumor-initiating stem cell shapes its microenvironment into an immunosuppressive barrier and pro-tumorigenic niche. <i>Cell Reports</i> , 2021, 36, 109674.	6.4	33
16	Relating Gut Microbiome and Its Modulating Factors to Immunotherapy in Solid Tumors: A Systematic Review. <i>Frontiers in Oncology</i> , 2021, 11, 642110.	2.8	32
17	Advances in the management of gastrointestinal cancersâ€an upcoming role of immune checkpoint blockade. <i>Journal of Hematology and Oncology</i> , 2015, 8, 86.	17.0	31
18	Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy. <i>Diseases (Basel)</i> , 2021, 11, 106.	2.5	31

#	ARTICLE	IF	CITATIONS
19	A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study.. Journal of Clinical Oncology, 2018, 36, 217-217.	1.6	28
20	Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies. Journal of Gastrointestinal Cancer, 2018, 49, 107-115.	1.3	27
21	Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma. Clinical Colorectal Cancer, 2019, 18, 81-90.	2.3	25
22	Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice. Gastroenterology, 2020, 158, 1433-1449.e27.	1.3	23
23	Molecular Targeted Therapy in Hepatocellular Carcinoma: From Biology to Clinical Practice and Future. Current Treatment Options in Oncology, 2014, 15, 380-394.	3.0	21
24	Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors. , 2021, 9, e003019.		20
25	Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting–its impact on clinical practice. Journal of Hematology and Oncology, 2015, 8, 92.	17.0	17
26	Phase II trial of cabozantinib (Cabo) plus durvalumab (Durva) in chemotherapy refractory patients with advanced mismatch repair proficient/microsatellite stable (pMMR/MSS) colorectal cancer (CRC): CAMILLA CRC cohort results.. Journal of Clinical Oncology, 2022, 40, 135-135.	1.6	17
27	Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): Results of the international, randomized phase 3 RESORCE trial.. Journal of Clinical Oncology, 2017, 35, 344-344.	1.6	16
28	Clinical Outcome of Ampullary Carcinoma: Single Cancer Center Experience. Journal of Oncology, 2019, 2019, 1-7.	1.3	15
29	Cabozantinib (cabo) combined with durvalumab (durva) in gastroesophageal (GE) cancer and other gastrointestinal (GI) malignancies: Preliminary phase Ib CAMILLA study results.. Journal of Clinical Oncology, 2020, 38, 4563-4563.	1.6	13
30	Comparison of KRAS and PIK3CA gene status between primary tumors and paired metastases in colorectal cancer. OncoTargets and Therapy, 2016, 9, 2329.	2.0	12
31	Recent advances in cancer immunotherapy. Journal of Hematology and Oncology, 2017, 10, 96.	17.0	12
32	Comparison of Efficacy of Systemic Therapies in Advanced Hepatocellular Carcinoma: Updated Systematic Review and Frequentist Network Meta-Analysis of Randomized Controlled Trials. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 145-154.	3.7	12
33	Niraparib in metastatic pancreatic cancer after previous chemotherapy (NIRA-PANC): A phase 2 trial.. Journal of Clinical Oncology, 2019, 37, TPS4168-TPS4168.	1.6	12
34	Controversies in Rectal Cancer Treatment and Management. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 136-146.	3.8	10
35	Prognostic impact of BRAF V600E mutation in patients with non-metastatic colorectal cancer with microsatellite instability: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2018, 36, 3597-3597.	1.6	8
36	A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment. Cancer Chemotherapy and Pharmacology, 2021, 88, 485-497.	2.3	7

#	ARTICLE	IF	CITATIONS
37	Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review. <i>Journal of Pancreatic Cancer</i> , 2020, 6, 107-115.	0.9	5
38	A phase Ib trial of cabozantinib in combination with durvalumab (MEDI4736) in previously treated patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies (CAMILLA).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS56-TPS56.	1.6	5
39	A phase II study of perioperative mFOLFOX chemotherapy plus pembrolizumab combination in patients with potentially resectable adenocarcinoma of the esophageal, gastroesophageal junction (GEJ), and stomach.. <i>Journal of Clinical Oncology</i> , 2022, 40, 329-329.	1.6	5
40	Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2682.	2.4	4
41	Is obesity a risk factor in cancer patients with COVID-19?. <i>Future Oncology</i> , 2021, 17, 3541-3544.	2.4	4
42	Pre-operative Carboplatin/Paclitaxel <i>Versus</i> 5-Fluorouracil (5-FU)-based Chemoradiotherapy for Older Adults With Esophageal Cancer. <i>Anticancer Research</i> , 2022, 42, 59-66.	1.1	4
43	Prognostic impact of obesity in cancer patients with COVID-19 infection: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18578-e18578.	1.6	3
44	Total neoadjuvant therapy compared with standard therapy in locally advanced rectal cancer: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 709-709.	1.6	3
45	A phase II study of perioperative mFOLFOX plus pembrolizumab combination in patients with potentially resectable adenocarcinoma of the esophageal, gastroesophageal junction (GEJ) and stomach.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4047-4047.	1.6	3
46	Colorectal Adenocarcinoma Presenting With Isolated Metastasis to the Cortical Bone and Bone Marrow: A Case Report and Review of the Literature. <i>Clinical Colorectal Cancer</i> , 2021, 20, e150-e154.	2.3	2
47	Biomarker analysis for UPCI 14-118: Phase II study of pembrolizumab in combination with azacitidine in patients with refractory metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 173-173.	1.6	2
48	Phase Ib/IIa trial of CEND ¹ in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colorectal, and appendiceal cancers (CENDIFOX).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4195-TPS4195.	1.6	2
49	Pass quantity, focus on quality. <i>Journal of Hematology and Oncology</i> , 2015, 8, 27.	17.0	1
50	A novel outpatient regimen in management of fluoropyrimidine-induced cardiotoxicity.. <i>Journal of Clinical Oncology</i> , 2021, 39, e15613-e15613.	1.6	1
51	Abstract P13: Prospective voluntary SARS-CoV-2 virus and anti-COVID-19 antibody tests in asymptomatic medical and research staff who work in direct contact with cancer patients: A single center study. , 2021, , .		0
52	Early detection of pancreatic cancers by novel nanobiosensor-based protease biomarkers using hierarchical decision structure.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16273-e16273.	1.6	0
53	Increased neutrophil infiltration and lower prevalence of tumor mutation burden and microsatellite instability are hallmarks of RAS mutant colorectal cancers.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3563-3563.	1.6	0
54	Efficacy of immunotherapy in hepatocholangiocarcinoma (HCC-CC): Proof of concept.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16194-e16194.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Novel prognostic biomarkers and their association with survival in pancreatic cancers.. Journal of Clinical Oncology, 2019, 37, 296-296.	1.6	0
56	Classifying inpatient deaths among liver and intrahepatic bile duct cancer and the effect of palliative care utilization on overall health care burden.. Journal of Clinical Oncology, 2020, 38, e16673-e16673.	1.6	0
57	Similar response rates and survival with PARPi treatments for patients harboring somatic versus germline BRCA mutations: A meta-analysis and systematic review.. Journal of Clinical Oncology, 2020, 38, e16802-e16802.	1.6	0
58	Patient characteristics and outcomes at the University of Kansas Cancer Urgent Care (CUC).. Journal of Clinical Oncology, 2020, 38, e19154-e19154.	1.6	0
59	Deaths among pancreatic cancer in-hospital, and the utilization of palliative care.. Journal of Clinical Oncology, 2020, 38, e16803-e16803.	1.6	0
60	CA209-8YD: A phase I/II trial of rucaparib in combination with ramucirumab with or without nivolumab in previously treated advanced gastroesophageal adenocarcinoma (GEA) (RiME).. Journal of Clinical Oncology, 2022, 40, TPS377-TPS377.	1.6	0
61	Phase II trial of moderate dose omega-3 acid ethyl esters for colorectal cancer prevention in patients with lynch syndrome (COLYNE).. Journal of Clinical Oncology, 2022, 40, TPS209-TPS209.	1.6	0
62	Real-world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionuclide therapy.. Journal of Clinical Oncology, 2022, 40, 504-504.	1.6	0
63	Abstract P4-10-03: Immunogenicity of SARS-CoV-2 vaccination in subjects on active treatment for breast cancer. Cancer Research, 2022, 82, P4-10-03-P4-10-03.	0.9	0
64	Association of pathologic response and survival after peri-operative therapy in resected pancreatic adenocarcinoma: KU cancer center experience.. Journal of Clinical Oncology, 2022, 40, e16254-e16254.	1.6	0
65	Bringing experimental therapeutics clinical trials network (ETCTN) to underrepresented population.. Journal of Clinical Oncology, 2022, 40, 6542-6542.	1.6	0